Joined Today: 14

DEPO Depomed, Stock Message Board

All Messages

DEPO Message Board Home | Join The DEPO Group |

#64: Depomed Initiates Phase 3 Program in Menopausal Hot Flashes
TheMachine	September 20, 2008 01:12:53 AM
Depomed, Inc. (NASDAQ:DEPO) announced today the enrollment and dosing of the first patient in Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed’s... view message ignore post recommend post

#63: Depomed to Present at the BIO CEO & Investor Conference
TheMachine	February 5, 2008 08:57:51 AM
Depomed, Inc. (NASDAQ:DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, Feb. 12, 2008 at 11 AM ET during the... view message ignore post recommend post

#62: Depomed Receives FDA Approval for 1000 mg Strength Tablets of Glumetza
TheMachine	January 29, 2008 02:21:33 AM
Depomed, Inc. (NASDAQ:DEPO) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the 1000 mg strength tablets of GlumetzaTM... view message ignore post recommend post

#61: Depomed Receives FDA Approval for 1000 mg Strength Tablets of Glumetza
NewsBot	January 16, 2008 09:31:34 AM
Depomed, Inc. (NASDAQ:DEPO) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the 1000 mg strength tablets of GlumetzaTM (metformin... view message ignore post recommend post

#60: DEPO News Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
NewsBot	April 2, 2007 07:00:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has filed a prior approval supplement with the U.S. Food and Drug Administration (FDA) seeking... view message ignore post recommend post

#59: DEPO News Depomed Appoints David Zenoff to Board of Directors
NewsBot	March 23, 2007 04:00:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that David B. Zenoff has been appointed to the company’s board of directors. Dr. Zenoff brings to... view message ignore post recommend post

#58: DEPO News Depomed Reports 2006 Year End Financial Results
NewsBot	March 14, 2007 01:00:00 PM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced its financial results for the year ended December 31, 2006. For the full year, revenues totaled $9.6... view message ignore post recommend post

#57: DEPO News Depomed Files Investigational New Drug Application for Gabapentin GR for the Treatment of Postmenopausal Hot Flashes
NewsBot	March 12, 2007 04:00:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug... view message ignore post recommend post

#56: DEPO News Depomed Completes Patient Enrollment in Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
NewsBot	March 8, 2007 04:00:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that it has completed patient enrollment in the pivotal registration Phase 3 clinical trial designed to... view message ignore post recommend post

#55: DEPO News Depomed to Announce Fourth Quarter and Year End 2006 Financial Results on Wednesday, March 14
NewsBot	February 28, 2007 04:00:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter and year end financial results for 2006 after the market closes on... view message ignore post recommend post

#54: DEPO News Depomed to Present at the Oppenheimer Pain Management Conference
NewsBot	February 27, 2007 04:00:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that chairman, president and chief executive officer, John W. Fara, Ph.D., will present on Tuesday,... view message ignore post recommend post

#53: DEPO News Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
NewsBot	December 21, 2006 02:00:00 PM
MENLO PARK, Calif. & EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) and Esprit Pharma, Inc. announced today that Esprit has paid Depomed the $10 million license fee... view message ignore post recommend post

#52: DEPO News Depomed Announces Sweeping Interim Victory in Litigation against Ivax
NewsBot	December 20, 2006 01:04:00 PM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced a favorable “Markman” decision by Judge Charles Breyer of the United States District Court for ... view message ignore post recommend post

#51: DEPO News Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
NewsBot	December 18, 2006 05:00:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that it has delivered a notice to Esprit Pharma, Inc. regarding Esprit’s breaches of the... view message ignore post recommend post

#50: DEPO News Depomed Announces Equity Financing Commitment of Up to $30 Million
NewsBot	December 12, 2006 05:00:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that it has received a commitment of up to $30 million in common stock equity financing from Azimuth... view message ignore post recommend post

Group Home | Login if you want to post a message